Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
0.7200
-0.0122 (-1.67%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Spero Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 52.89 | 76.33 | 109.11 | 112.58 | 85.21 | Upgrade
|
| Short-Term Investments | - | - | - | 33.82 | 41.7 | Upgrade
|
| Cash & Short-Term Investments | 52.89 | 76.33 | 109.11 | 146.4 | 126.91 | Upgrade
|
| Cash Growth | -30.71% | -30.04% | -25.47% | 15.36% | 54.68% | Upgrade
|
| Accounts Receivable | 49.39 | 49.15 | - | - | - | Upgrade
|
| Other Receivables | 3.09 | 1.55 | 1.08 | 2.64 | 6.18 | Upgrade
|
| Receivables | 52.48 | 50.7 | 1.08 | 2.64 | 6.18 | Upgrade
|
| Prepaid Expenses | 1.91 | 4.18 | 3.38 | 8.83 | 6.06 | Upgrade
|
| Total Current Assets | 107.28 | 131.21 | 113.57 | 157.87 | 139.15 | Upgrade
|
| Property, Plant & Equipment | 3.11 | 4.16 | 5.49 | 7.56 | 8.78 | Upgrade
|
| Long-Term Accounts Receivable | - | 46.59 | - | - | - | Upgrade
|
| Other Long-Term Assets | 0.15 | 0.44 | 5.74 | 5.64 | 5.52 | Upgrade
|
| Total Assets | 110.54 | 182.39 | 124.8 | 171.07 | 153.45 | Upgrade
|
| Accounts Payable | 7.31 | 1.38 | 0.62 | 1.1 | 1.16 | Upgrade
|
| Accrued Expenses | 17.27 | 6.56 | 8.53 | 14.35 | 12.24 | Upgrade
|
| Current Portion of Leases | 1.75 | 1.72 | 1.69 | 1.36 | 0.95 | Upgrade
|
| Current Income Taxes Payable | 0.17 | 0.39 | - | - | - | Upgrade
|
| Current Unearned Revenue | 22.12 | 27.11 | 10.37 | 1.86 | - | Upgrade
|
| Other Current Liabilities | 0.46 | - | 0.45 | - | - | Upgrade
|
| Total Current Liabilities | 49.07 | 37.15 | 21.65 | 18.67 | 14.34 | Upgrade
|
| Long-Term Debt | - | - | - | 48.41 | - | Upgrade
|
| Long-Term Leases | 2.55 | 3.83 | 4.96 | 5.97 | 6.89 | Upgrade
|
| Long-Term Unearned Revenue | 12.8 | 34.43 | 22.17 | 8.79 | - | Upgrade
|
| Other Long-Term Liabilities | - | 0.09 | 0.1 | 0.94 | 0.18 | Upgrade
|
| Total Liabilities | 64.42 | 75.5 | 48.87 | 82.78 | 21.41 | Upgrade
|
| Common Stock | 0.06 | 0.05 | 0.05 | 0.03 | 0.03 | Upgrade
|
| Additional Paid-In Capital | 505.71 | 497.91 | 489.76 | 455.72 | 409.72 | Upgrade
|
| Retained Earnings | -459.64 | -391.07 | -413.88 | -367.46 | -277.71 | Upgrade
|
| Comprehensive Income & Other | - | - | - | -0 | -0.01 | Upgrade
|
| Total Common Equity | 46.12 | 106.89 | 75.93 | 88.29 | 132.04 | Upgrade
|
| Shareholders' Equity | 46.12 | 106.89 | 75.93 | 88.29 | 132.04 | Upgrade
|
| Total Liabilities & Equity | 110.54 | 182.39 | 124.8 | 171.07 | 153.45 | Upgrade
|
| Total Debt | 4.3 | 5.54 | 6.65 | 55.75 | 7.84 | Upgrade
|
| Net Cash (Debt) | 48.59 | 70.79 | 102.46 | 90.65 | 119.07 | Upgrade
|
| Net Cash Growth | -31.36% | -30.91% | 13.02% | -23.86% | 55.64% | Upgrade
|
| Net Cash Per Share | 0.90 | 1.34 | 2.73 | 2.93 | 5.32 | Upgrade
|
| Filing Date Shares Outstanding | 55.9 | 53.87 | 52.57 | 32.76 | 29.5 | Upgrade
|
| Total Common Shares Outstanding | 54.59 | 53 | 52.46 | 32.39 | 29.26 | Upgrade
|
| Working Capital | 58.2 | 94.06 | 91.92 | 139.2 | 124.8 | Upgrade
|
| Book Value Per Share | 0.84 | 2.02 | 1.45 | 2.73 | 4.51 | Upgrade
|
| Tangible Book Value | 46.12 | 106.89 | 75.93 | 88.29 | 132.04 | Upgrade
|
| Tangible Book Value Per Share | 0.84 | 2.02 | 1.45 | 2.73 | 4.51 | Upgrade
|
| Machinery | 1.55 | 1.55 | 1.55 | 1.76 | 1.76 | Upgrade
|
| Construction In Progress | - | - | - | - | 0.04 | Upgrade
|
| Leasehold Improvements | 1.64 | 1.64 | 1.64 | 1.64 | 1.64 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.